



Company Announcement

Nykode Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Oslo, Norway, September 9, 2026 — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that its CEO, Michael Engsig, and CSO and Co-founder, Agnete Fredriksen, will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14–16, 2026, in New York, where they will present and host one-on-one meetings with investors.

Presentation Details:

Event: H.C. Wainwright 28th Annual Global Investment Conference

Date: Wednesday, September 16, 2026

Time: 11:30 a.m. ET / 5:30 p.m. CEST

Location: Lotte New York Palace, New York City

Room: Holmes II – 4th Floor

During the conference, management will discuss Nykode's recent progress and key value drivers, including its lead program, abi-suva, currently being evaluated in the randomized Phase 2 Abili-T trial in first-line head and neck cancer; VB10.NEO, an individualized neoantigen immunotherapy designed to generate personalized, tumor-specific immune responses; and its immune tolerance platform.

Investors interested in scheduling a one-on-one meeting with Nykode management should contact their H.C. Wainwright representative.

The presentation slides will be available in the Investors section of the Company's website at <https://nykode.com/investors/events-presentations/>

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are abi-suva, a therapeutic immunotherapy for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of late-line r/m cervical cancer. Abi-suva is currently being further developed in first line head and neck cancer with the randomized Abili-T trial with interim results within 2027.



VB10.NEO, an individualized cancer neoantigen immunotherapy, has been investigated in two trials with more than 10 different indications.

Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at <http://www.nykode.com>.

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:

IR@nykode.com

Nykode Therapeutics ASA

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway